Brings AI-driven Antibody Testing to the Masses with the Launch of its SARS-CoV-2 Test

SALT LAKE CITY, Feb. 28, 2023 /PRNewswire/ —, a biotechnology diagnostics company, announces the full commercial release of its SARS-CoV-2 Total Antibody Test. This innovative solution uses an agglutination-based method combined with an AI-driven mobile application to deliver semi-quantitative antibody results at the point of care, providing fast and accurate diagnostic results without the need for complex diagnostic instrumentation.

The test, which takes under 3 minutes from the sample to the result and requires an internet connection, is easy to use and can be done at home or in a professional setting. With a 97.6% sensitivity and 100% specificity, the SARS-CoV-2 Total Antibody Test is a reliable solution for individuals seeking to understand their exposure to COVID-19 and their level of immunity to the virus.

The full commercial release of this new product marks a major milestone for and will be available for purchase through select distribution channels. The test obtained a CE Mark in May 2022.

“We are proud to bring this groundbreaking product to the larger European market, which will significantly impact the lives of individuals and communities affected by COVID-19,” said Rian Wendling, CEO of “Our innovative approach to antibody testing offers fast, accurate results, and the ability to make informed decisions about one’s health and well-being.”

In September of 2022, announced its partnership with Opto, an Athroa company, to commercialize the SARS-CoV-2 Antibody Test in Europe. With this partnership, the company aims to make antibody insights more accessible globally.

Future indications include blood typing and cardiac markers.

About unlocks the unique advantages of agglutination-based testing to bring low-cost, quantitative, and ultra-fast blood-based diagnostics to any environment. Their AI-enabled platform provides personalized insights anywhere an internet connection is available.

For more information about and its SARS-CoV-2 Total Antibody Test, please visit the company’s website at

Media Contact:
Rian Wendling